Terns Pharmaceuticals, Inc. (TERN)
After hours:
| Previous Close | 2.0500 |
| Open | 2.0700 |
| Bid | 2.1000 x 900 |
| Ask | 2.4000 x 1800 |
| Day's Range | 2.0700 - 2.2600 |
| 52 Week Range | 1.4500 - 13.7700 |
| Volume | |
| Avg. Volume | 161,404 |
| Market Cap | 56.878M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0050 |
| Earnings Date | Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- GlobeNewswire
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indic
- GlobeNewswire
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Cor
- Zacks
All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy
Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
